Angio360 Diagnostics

Introductions

Angio360 Diagnostics LLC is a privately held pre-development company specializing in antibody-based products focused on improving the detection and treatment of canine and human cancers. Utilizing patented biomarkers uniquely associated with tumor angiogenesis/blood vessel growth, Angio360’s AngioTracer product line will revolutionize the cancer diagnostic market through earlier detection of tumors and rapid assessment of treatment efficacy. Application of these tools will allow for more precise and efficient treatments, thus reducing the overall cost of care and improving patient outcomes. Marketed to veterinarians seeking to diagnose cancer, pharmaceutical companies engaged in late-stage drug development, and oncologists seeking efficiency in monitoring a patient’s therapeutic response, Angio360’s product line’s broad application has the potential to rapidly advance the landscape of cancer diagnostics.